Transplantation of a combination of CD133+ and CD34+ selected progenitor cells from alternative donors

被引:75
|
作者
Lang, P
Bader, P
Schumm, M
Feuchtinger, T
Einsele, H
Führer, M
Weinstock, C
Handgretinger, R
Kuci, S
Martin, D
Niethammer, D
Greil, J
机构
[1] Univ Tubingen, Univ Childrens Hosp, Dept Pediat Oncol, D-72076 Tubingen, Germany
[2] Univ Tubingen, Dept Internal Med, Tubingen, Germany
[3] Univ Munich, Childrens Univ Hosp, Munich, Germany
[4] Univ Tubingen, Dept Transfus Med, Tubingen, Germany
[5] St Jude Childrens Res Hosp, Memphis, TN 38105 USA
关键词
stem cell transplantation; alternative donors; CD34(+) selection; CD133(+)-selection; haploidentical;
D O I
10.1046/j.1365-2141.2003.04747.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Positive selected haematopoietic stem cells are increasingly used for allogeneic transplantation with the CD34 antigen employed in most separation techniques. However, the recently described pentaspan molecule CD133 appears to be a marker of more primitive haematopoietic progenitors. Here we report our experience with a new CD133-based selection method in 10 paediatric patients with matched unrelated (n = 2) or mismatched-related donors (n = 8). These patients received a combination of stem cells (median = 29.3 x 10(6)/kg), selected with either anti-CD34 or anti-CD133 coated microbeads. The proportion of CD133(+) selected cells was gradually increased from patient to patient from 10% to 100%. Comparison of CD133(+) and CD34(+) separation procedures revealed similar purity and recovery of target populations but a lower depletion of T cells by CD133(+) selection (3.7 log vs. 4.1 log, P < 0.001). Both separation procedures produced >90% CD34(+)/CD133(+) double positive target cells. Engraftment occurred in all patients (sustained primary, n = 8; after reconditioning, n = 2). No primary acute graft versus host disease (GvHD) greater than or equal to grade II or chronic GvHD was observed. The patients showed a rapid platelet recovery (median time to independence from substitution = 13.5 d), whereas T cell regeneration was variable. Five patients are alive with a median follow-up of 10 months. Our data demonstrates the feasibility of CD133(+) selection for transplantation from alternative donors and encourages further trials with total CD133(+) separated grafts.
引用
收藏
页码:72 / 79
页数:8
相关论文
共 50 条
  • [1] DIFFERENTIAL NUMBER OF CD34+, CD133+ AND CD34+/CD133+ CELLS IN PERIPHERAL BLOOD OF PATIENTS WITH CONGESTIVE HEART FAILURE
    Fritzenwanger, M.
    Lorenz, F.
    Jung, C.
    Fabris, M.
    Thude, H.
    Barz, D.
    Figulla, H. R.
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2009, 14 (03) : 113 - 117
  • [2] Differential number of CD34+, CD133+ and CD34+/CD133+ cells in peripheral blood of patients with congestive heart failure
    M Fritzenwanger
    F Lorenz
    C Jung
    M Fabris
    H Thude
    D Barz
    HR Figulla
    European Journal of Medical Research, 14 (3)
  • [3] CD34+ and CD133+ cells in cord blood of term newborns
    Roumiantsev, Sergey A.
    Boyakova, Elena V.
    Shutieva, Anisya B.
    Mayorova, Olga A.
    Roumiantsev, Alexander G.
    EXPERIMENTAL HEMATOLOGY, 2008, 36 (07) : S62 - S62
  • [4] Allogeneic transplantation of CD34+ selected peripheral blood progenitor cells from related donors.
    UrbanoIspizua, A
    Rozman, C
    Marin, P
    Martinez, C
    Briones, J
    Carreras, E
    Rovira, M
    Feliz, P
    Merino, A
    Sierra, J
    Mazzara, R
    Montserrat, E
    EXPERIMENTAL HEMATOLOGY, 1996, 24 (09) : 118 - 118
  • [5] Allogeneic transplantation of CD34+ selected peripheral blood progenitor cells from matched related donors
    UrbanoIspizua, A
    Rozman, C
    Marin, P
    Martinez, C
    Briones, J
    Carreras, E
    Rovira, M
    Feliz, P
    Merino, A
    Sierra, J
    Mazzara, R
    Montserrat, E
    BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 : 612 - 612
  • [6] Factors influencing spontaneous mobilization of CD34+ and CD133+ progenitor cells after myocardial infarction
    Turan, R. G.
    Brehm, M.
    Koestering, M.
    Tobias, Z.
    Bartsch, T.
    Steiner, S.
    Picard, F.
    Ebner, P.
    Schannwell, C. M.
    Strauer, B. E.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2007, 37 (11) : 842 - 851
  • [7] Autologous CD34+ and CD133+ stem cells transplantation in patients with end stage liver disease
    Salama, Hosny
    Zekri, Abdel-Rahman N.
    Bahnassy, Abeer A.
    Medhat, Eman
    Halim, Hanan A.
    Ahmed, Ola S.
    Mohamed, Ghada
    Al Alim, Sheren A.
    Sherif, Ghada M.
    WORLD JOURNAL OF GASTROENTEROLOGY, 2010, 16 (42) : 5297 - 5305
  • [8] Expression of CD34, CD133 and CD41 on the Mk progenitor cells produced from normal bone marrow (BM) CD34+ CD133+ cells differs from that of unmanipulated BM Mk progenitor cells.
    Charrier, S
    Boiret, N
    Fouassier, M
    Berger, J
    John, SR
    Rapatel, C
    Lioret, F
    Camilleri, L
    Bonhomme, J
    Berger, MG
    BLOOD, 2001, 98 (11) : 335B - 336B
  • [9] Transplantation of CD34+ hematopoietic progenitor cells
    Berenson, RJ
    Shpall, EJ
    AuditoreHargreaves, K
    Heimfeld, S
    Jacobs, C
    Krieger, MS
    CANCER INVESTIGATION, 1996, 14 (06) : 589 - 596
  • [10] Differential gene expression profiling of CD34+ CD133+ umbilical cord blood hematopoietic stem progenitor cells
    He, XH
    Gonzalez, V
    Tsang, A
    Thompson, J
    Tsang, TC
    Harris, DT
    STEM CELLS AND DEVELOPMENT, 2005, 14 (02) : 188 - 198